Alzaabi Manal, Taguri Abdel Hakim, Elbarky Ahmed
Sheikh Khalifa Medical City, Abu Dhabi, United Arab Emirates.
Assistant Professor of Ophthalmology in Benha Faculty of Medicine, Egypt.
Am J Ophthalmol Case Rep. 2020 Sep 11;20:100922. doi: 10.1016/j.ajoc.2020.100922. eCollection 2020 Dec.
To describe a case of spontaneous anterior migration of intravitreal fluocinolone acetonide (Iluvien®) implant in a pseudophakic eye with intact posterior capsule.
A 60-year old woman with proliferative diabetic retinopathy underwent uneventful pars plana vitrectomy and phacoemulsification with posterior chamber intraocular lens (PCIOL) implants in both eyes. She developed diabetic macular edema (DME) in her right eye which failed to respond to repeated intravitreal injections of Aflibercept 2mg/0.05ml (Eylea®). The patient received an intravitreal Iluvien® implant to treat the recalcitrant DME after she showed a favorable temporary response to dexamethasone intravitreal implant (Ozurdex™).Six months later she presented with pain in the right eye due to elevated intraocular pressure (IOP). The Iluvien® implant was found to be dislodged into the anterior chamber (AC) in the presence of an intact posterior capsule and stable PCIOL implant. The migrated Iluvien implant was removed and IOP was controlled with a glaucoma drainage valve as it failed to respond to maximum anti-glaucoma medication.
Intravitreal Iluvien® implant could migrate into the AC in a previously vitrectomized eyes in the presence of an intact posterior capsule.
描述一例在人工晶状体眼且后囊完整的情况下,玻璃体内注射曲安奈德(Iluvien®)植入物自发向前移位的病例。
一名60岁患有增殖性糖尿病视网膜病变的女性接受了双眼平坦部玻璃体切除术和白内障超声乳化吸除术,并植入了后房型人工晶状体(PCIOL),手术过程顺利。她右眼出现糖尿病性黄斑水肿(DME),对多次玻璃体内注射阿柏西普2mg/0.05ml(Eylea®)无反应。在患者对玻璃体内注射地塞米松植入物(Ozurdex™)表现出良好的暂时反应后,接受了玻璃体内Iluvien®植入物治疗顽固性DME。六个月后,她因眼压升高出现右眼疼痛。发现在后囊完整且PCIOL植入物稳定的情况下,Iluvien®植入物已移位至前房(AC)。取出移位的Iluvien植入物,由于其对最大剂量的抗青光眼药物无反应,故采用青光眼引流阀控制眼压。
在人工晶状体眼且后囊完整的情况下,玻璃体内Iluvien®植入物可能会移位至前房。